Provectus Pharmaceuticals, Inc. will present data on PV-10 in a poster presentation at the American Association for Cancer Research Annual Meeting in Washington, DC. The PV-10 combination therapy poster, based upon an abstract entitled "Combination of PV-10 immuno-chemoablation and systemic anti-CTLA-4 antibody therapy in murine models of melanoma," is authored by Eric Wachter, Savannah Blair, Jamie Singer, and Craig Dees, and will be presented on April 10, 2013. PV-10 is Provectus Pharmaceuticals's novel oncology drug designed to selectively target and destroy cancer cells without harming surrounding healthy tissue, significantly reducing potential for systemic side effects.